

EXPRESS MAIL CERTIFICATE

Date 12/11/01 Label No. EV004807234-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202 by "Express Mail Post Office to Addressee" service.

B.W. LEE
Name (Print)

B.W. Lee
Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Docket No.: 1034/1H570 US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Peter H. ST. GEORGE-HYSLOP, et al.

Serial No.: 09/945,258

Confirmation No.: 1969

Filed: August 31, 2001

For: PROTEINS RELATED TO SCHIZOPHRENIA AND USES THEREOF


INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested



#5
2/2/02
TECH CENTER 1600/2901
DEC 19 2001
RECEIVED

that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first Office Action on the merits of the application has been received.


The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.


Respectfully submitted,

Dated: December 11, 2001

A handwritten signature in dark ink, appearing to read "Paul F. Fehlner", with a horizontal line drawn underneath it.

Paul F. Fehlner, Ph.D.
Registration No. 35,135
Attorney for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, NY 10022
(212) 527-7700



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 1 OF 4
(REV. 7-80)

TECH CENTER 1600/2900

DEC 19 2001

RECEIVED

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1034/1H570US1

SERIAL NO: 09/945,258

APPLICANT: ST. GEORGE-HYSLOP, et al.

FILING DATE: August 31, 2000

CONFIRMATION NO: 1969

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
	1. 6,020,143	02/01/00	St. George-Hyslop et al.	435	7.1	07/03/97
	2. 5,986,054	11/16/99	St. George-Hyslop et al.	530	350	01/26/96

U.S. PENDING APPLICATIONS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>NAME</u>	<u>FILING DATE</u>
	3. 09/541,094	St. George-Hyslop et al.	03/31/00
	4. 09/227,725	St. George-Hyslop et al.	01/08/99

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u> <u>YES</u> <u>NO</u>
-------------------------------	----------------------------	-------------	----------------	--------------	-----------------	--

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)***EXAMINER
INITIALS

5. Baker, "Notch signaling in the nervous system. Pieces still missing from the puzzle", Bioessays 2000;

22:264-273

2 6. Borchelt et al., "Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate Abeta1-42/1-40 Ratio

In Vitro and In Vivo", Neuron 1996; 17:1005-1013

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1034/1H570US1
APPLICANT: ST. GEORGE-HYSLOP, et al.SERIAL NO: 09/945,258
FILING DATE: August 31, 2001
CONFIRMATION NO: 1969*EXAMINER
INITIALS

- 3 7. Brzustowicz et al., "Location of a Major Susceptibility Locus for Familial Schizophrenia on Chromosome 1q21-q22", Science 2000; 288:678-682 ✓
- 4 8. Citron et al., "Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid B-protein in both transfected cells and transgenic mice", Nature Med. 1997; 3:67-72 ✓
- 5 9. DeStrooper et al., Nature 1998; 391:387-390 ✓
- 6 10. Duff et al., "Increased amyloid-B42(43) in brains of mice expressing mutant presenilin 1", Nature 1996; 383:710-713 ✓
- 7 11. Falkai et al., "Entorhinal Cortex Pre-Alpha Cell Clusters in Schizophrenia: Quantitative Evidence of a Developmental Abnormality", Biol Psychiatry 2000; 47:937-943 ✓
- 8 12. Handler et al., "Presenilin-1 regulates neuronal differentiation during neurogenesis", Development 2000 Jun; 127(12):2593-2606 ✓
- 9 13. Hartmann et al., "Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly", Curr Biol 1999; 15:719-727 ✓
- 10 14. Jones et al., "Mutation in codon 713 of the B amyloid precursor protein gene presenting with schizophrenia", Nature Genet 1992; 1:306-309 ✓
- 11 15. Levitan et al., "Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene", Nature 1995; 377:351-354 ✓
- 12 16. Martins et al., "High levels of amyloid-B protein from S182 (Glu246) familial Alzheimer's cells", NeuroReport 1995; 7:217-220 ✓

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1034/1H570US1
APPLICANT: ST. GEORGE-HYSLOP, et al.SERIAL NO: 09/945,258
FILING DATE: August 31, 2001
CONFIRMATION NO: 1969*EXAMINER
INITIALS

- 13 17. Scheuner et al., "Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease" is increased *in vivo* by the presenilin 1 and 2 and *APP* mutations linked to familial Alzheimer's disease", Nature Med. 1996; 2:864-870 ✓
- 14 18. Selkoe, Curr Opin Neurobiol 2000; 10:50-57 ✓
- 15 19. Shen J. et al., "Skeletal and CNS Defects in *Presenilin-1*-Deficient Mice", Cell 1997; 89:629-639 ✓
- 16 20. Stefan and Murray, "Schizophrenia: developmental disturbance of brain and mind?", Acta Paediatrica Suppl. 1997; 422:112-116 ✓
- 17 21. Wei and Hemmings, "The *NOTCH4* locus is associated with susceptibility to schizophrenia", Nature Genet 2000; 25:376-377 ✓
- 18 22. Wolozin et al., "Participation of Presenilin 2 in Apoptosis: Enhanced Basal Activity Conferred by an Alzheimer Mutation", Science 1996; 274:1710-1713 ✓
- 19 23. Wong PC et al., "Presenilin 1 is required for *Notch1* and *Dll1* expression in the paraxial mesoderm", Nature 1997; 387:288-292 ✓
- 20 24. Yu et al., "Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and BAPP processing", Nature 2000; 407:48-54 ✓
- 21 25. Boulianne et al., "Cloning and characterization of the *Drosophila* presenilin homologue", Neuro. Report (Fast Track) 1997; 8:1025-1029 ✓

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1034/1H570US1

APPLICANT: ST. GEORGE-HYSLOP, et al.

SERIAL NO: 09/945,258

FILING DATE: August 31, 2001

CONFIRMATION NO: 1969

*EXAMINER
INITIALS

26. Zhou et al., "Presenilin 1 interaction in the brain with a novel member of the Armadillo family",
Neuroreport 1997; 8:2085-2090

EXAMINER: _____

DATE CONSIDERED: _____

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.